Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management |
Jun 2023 |
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
How I Diagnose Low-Grade Myelodysplastic Syndromes |
May 2020 |
American Journal of clinical Pathology |
Myelodysplastic Syndromes (MDS) |
Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
Jan 2019 |
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry |
Jan 2019 |
Am J Hematol |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
HDAC4 inhibition disrupts TET2 function in high-risk MDS and AML |
Jul 2020 |
Aging |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study |
Apr 2024 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations |
Jun 2023 |
Advances in Therapy |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
Sep 2024 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria |
Sep 2024 |
Expert Review of Clinical Pharmacology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes |
Sep 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |